Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
PAVmed (PAVM) Receives a Buy From Lake Street
PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
Earnings Call Summary | PAVmed(PAVM.US) Q1 2024 Earnings Conference
The following is a summary of the PAVmed Inc. (PAVM) Q1 2024 Earnings Call Transcript:Financial Performance:PAVmed concluded Q1 2024 with a cash position of approximately $37.1 million.The average qua
Express News | PAVmed Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adj. EPS Results
PAVmed Inc Provides Informal Financial Performance Update
Reported Late Monday, PAVmed Q1 2024 Adj EPS $(0.99) Beats $(1.67) Estimate, Sales $1.010M Miss $1.053M Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.67) by 40.72 percent. This is a 42.77 percent increase over losses of $(1.73) per s
Press Release: PAVmed Provides Business Update and First Quarter 2024 Financial Results
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting
10-Q: Quarterly report
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technol
PAVmed Partners With Cancer Center to Advance Care
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage m
Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $26 From $30
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
No Data